Eli Lilly Corp. Stock
Eli Lilly Corp. Stock
Pros and Cons of Eli Lilly Corp. in the next few years
Pros
Cons
Performance of Eli Lilly Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eli Lilly Corp. | 0.310% | -0.762% | 1.588% | 106.426% | 33.239% | 345.394% | 583.010% |
| Pfizer Inc. | -1.470% | -2.757% | -7.173% | -36.844% | -8.774% | -25.987% | -28.937% |
| Elanco Animal Health Inc. | -1.140% | -10.583% | -13.057% | 43.680% | -7.012% | -49.752% | - |
| Biogen Inc. | -1.850% | -4.025% | -10.512% | -32.666% | -23.643% | -20.155% | -10.512% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Eli Lilly and Company (LLY) appears to have demonstrated strong financial performance in recent years. As a leading pharmaceutical company, LLY's financial statements show growth in key areas such as total assets, net income, and revenue. However, a thorough analysis is needed to identify the potential upsides and downsides of the company's financial performance. This will allow investors to make more informed decisions about the stability and growth potential of LLY.
*Pros: *
Growing revenue and net income: Over the years, LLY has experienced continued growth in total revenue, from $24.54 billion in 2020 to $28.72 billion in 2022. This growth is a positive indicator of the company's strong performance and financial health. Furthermore, LLY's net income has also increased from $6.19 billion in 2020 to $6.24 billion in 2022, showcasing the company's ability to generate consistent profits.
Comments